Destiny Pharma
plc
("Destiny
Pharma" or "the Company")
2024 Annual General
Meeting and Statement
Brighton, United Kingdom ‐ 12 June 2024
‐ Destiny Pharma plc (AIM: DEST) a clinical
stage innovative biotechnology company focused on the development
of novel medicines that can prevent life‐threatening infections,
will today hold its 2024 Annual General Meeting (AGM) at 11am
BST.
Ahead of the formal proceedings of
the Meeting, Sir Nigel Rudd, Chairman of Destiny
Pharma, will make the following
statement:
"We continue to believe XF-73 Nasal has enormous market
potential and can make a huge difference in the prevention of
surgical site infections, and the reduction in the usage of
antibiotics.
As
announced in our Full Year Results, the Company and Board have been
focused on seeking support to advance the XF-73 Nasal programme
through Phase 3 clinical trials. While licencing activities
continue, given our current cash runway, feedback from potential
partners has led us to evaluate a range of strategic options. Our
review of these options has continued since the Full Year Results
and we intend to provide an update to the market in the coming
weeks."
Immediately following the conclusion
of the AGM, Chris Tovey, Chief Executive Officer of Destiny Pharma,
will make a short corporate presentation that will be followed by a
Q&A session.
Shareholders that wish to attend the
AGM remotely should register for the event in advance by using the
following link:
https://www.investormeetcompany.com/destiny‐pharma‐plc/register‐investor
For further information, please
contact:
Destiny Pharma plc
Chris Tovey, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
FTI Consulting
Ben Atwell / Simon Conway
+44 (0) 203 727 1000
destinypharma@fticonsulting.com
Shore Capital (Nominated Adviser and
Broker)
Daniel Bush / James Thomas / Lucy
Bowden
+44 (0) 207 408 4090
About Destiny Pharma
Destiny Pharma is an innovative,
clinical-stage biotechnology company focused on the development and
commercialisation of novel medicines that can prevent
life-threatening infections. The Company's drug development
pipeline includes two late-stage assets XF-73 Nasal gel, a
proprietary drug targeting the prevention of post-surgical
staphylococcal hospital infections including MRSA and NTCD-M3, a
microbiome-based biotherapeutic for the prevention of C. difficile
infection (CDI) recurrence which is the leading cause of hospital
acquired infection in the US.
For further information on the
company, please visit
www.destinypharma.com.
About XF-73 Nasal
XF-73 is the lead drug candidate from
Destiny Pharma's XF platform, initially being developed for the
prevention of post-surgical staphylococcal infections, such as
methicillin-resistant Staphylococcus aureus (MRSA), which cause
significant complications and increased healthcare costs in the
hospital setting. XF‑73 has been awarded both Qualified Infectious Disease Product
(QIDP) and Fast Track status by the US FDA.
Forward looking statements
Certain information contained in this
announcement, including any information as to the company's
strategy, plans or future financial or operating performance,
constitutes "forward-looking statements". These forward looking
statements may be identified by the use of forward-looking
terminology, including the terms "believes", "estimates",
"anticipates", "projects", "expects", "intends", "aims", "plans",
"predicts", "may", "will", "seeks" "could" "targets" "assumes"
"positioned" or "should" or, in each case, their negative or other
variations or comparable terminology, or by discussions of
strategy, plans, objectives, goals, future events or intentions.
These forward-looking statements include all matters that are not
historical facts. They appear in a number of places throughout this
announcement and include statements regarding the intentions,
beliefs or current expectations of the Directors concerning, among
other things, the company's results of operations, financial
condition, prospects, growth, strategies and the industries in
which the company operates. The Directors of the company believe
that the expectations reflected in these statements are reasonable
but may be affected by a number of variables which could cause
actual results or trends to differ materially. Each forward-looking
statement speaks only as of the date of the particular statement.
By their nature, forward-looking statements involve risks and
uncertainties because they relate to events and depend on
circumstances that may or may not occur in the future or are beyond
the company's control. Forward looking statements are not
guarantees of future performance. Even if the company's actual
results of operations, financial condition and the development of
the industries in which the company operates are consistent with
the forward-looking statements contained in this document, those
results or developments may not be indicative of results or
developments in subsequent periods.
